Parkinson disease: electrophysiological (CNV) analysis related to pharmacological treatment

Electroencephalogr Clin Neurophysiol. 1986 Dec;64(6):521-4. doi: 10.1016/0013-4694(86)90189-6.

Abstract

The contingent negative variation (CNV) was studied in a group of patients with Parkinson's disease. Testing was carried out 3 times: after a pharmacological wash-out period and at 15 and 30 days after the start of treatment with L-DOPA and bromocriptine. Peak and area CNV increased significantly after each treatment. The post-imperative negative variation (PINV) was observed in 6 out of 10 patients. The correlation found between electrophysiological functioning (CNV) measures and pharmacological treatment supports the view that dopaminergic brain activity mediates the generation of the slow negative event-related brain potentials.

MeSH terms

  • Bromocriptine / therapeutic use*
  • Contingent Negative Variation / drug effects
  • Drug Therapy, Combination
  • Female
  • Humans
  • Levodopa / therapeutic use*
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology*

Substances

  • Bromocriptine
  • Levodopa